Category: 5308-25-8

5308-25-8, 1-Ethylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

5308-25-8, 1-(bromomethyl)-4-nitro-2-(trifluoromethyl)benzene (34 g, 120 mmol) obtained in above was dissolved in dichloromethane (300 mL), followed by stirring. The reaction solution was added with 1-ethylpiperazine (15.97 mL, 126 mmol) and DIPEA (27.2 mL, 156 mmol), followed by further stirring for about 3 hours at room temperature. The reaction mixture was diluted with dichloromethane, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (21.7 g, 57%). 1H-NMR Spectrum (300 MHz, DMSO-d6): delta 8.52 (d, 1H), 8.40 (s, 1H), 8.09 (d, 1H), 3.71 (s, 2H), 2.35 (m, 10H), 1.00 (t, 3H) MS (ESI+, m/z): 318 [M+H]+

The synthetic route of 5308-25-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; HANMI PHARM. CO., LTD; Bae, In Hwan; Son, Jung Beom; Han, Sang Mi; Kwak, Eun Joo; Kim, Ho Seok; Song, Ji Young; Byun, Eun Young; Jun, Seung Ah; Ahn, Young Gil; Suh, Kwee Hyun; US2014/371219; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5308-25-8,1-Ethylpiperazine,as a common compound, the synthetic route is as follows.

EXAMPLE 24 9-(2,4-Dichloroanilino)-4-[4-(4-ethyl- 1-piperazinyl)butyl]-3 4-dihydro-2H-[1,4]oxazino[2,3-g]quinoline-8-carbonitrile An amount of 120 mg (0.26 mmol) of 4-(4-chlorobutyl)-9-(2,4-dichloroanilino)-3,4-dihydro-2H-[1,4]oxazino[2,3-g]quinoline-8-carbonitrile was stirred in N,N-dimethylformramide (0.8 mL), and to this were added sodium iodide (55 mg, 0.36 mmol), tetrabutylammonium iodide (58 mg, 0.16 mmol), and 1-ethylpiperazine (0.26 mL, 2.1 mmol). The mixture was heated at 50 C. for three hours, after which an additional amount of 1-ethylpiperazine (0.26 mL, 2.1 mmol), was added. The mixture was heated at 60 C. for 3 hours, and subsequently evaporated to a yellow oil, stirred with saturated sodium bicarbonate solution, and extracted with dichloromethane. The organic layer was washed with saturated brine solution, dried over sodium sulfate, and evaporated to a yellow oil. Purification was performed by flash chromatography (10% acetone in dichloromethane, then 70:30:5=dichloromethane: methanol: ammonium hydroxide), to give a yellow solid (74 mg, 53% yield), m.p 97-98 C.; 1H NMR (DMSO-d6) delta 9.21 (s, 1H), 8.27 (s, 1H), 7.73 (d, 1H), 7.68 (s, 1H), 7.42 (dd, 2H), 6.70 (s, 1H), 4.27 (t, 2H), 3.49 (m, 4H), 2.31 (m, 12H), 1.62 (dd, J=7 Hz, 2H), 1.52 (dd, J=7 Hz, 2H), 0.97 (t, 3H);

5308-25-8, 5308-25-8 1-Ethylpiperazine 79196, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; American Home Products Corporation; US2003/65180; (2003); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5308-25-8,1-Ethylpiperazine,as a common compound, the synthetic route is as follows.

To a stirred solution of 1 -(bromomethyl)-4-nitro-2-(trifluoromethyl)benzene (step 1 intermediate) (4.0 g, 14.1 mmol) in dichloromethane (40 mL) were added N-ethylpiperazine(1.88 mL, 14.7 mmol) followed by N,N-diisopropylethylamine (DIPEA) (3.27 mL, 19.1 mmol) at RT. The mixture stirred at RT for 16 h. The reaction mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate solution followed by brine. The organic layer was dried over anhydrous sodium, filtered and concentrated under reduced pressure. The residue obtained was purified by column chromatography to yield 3.5 g of thedesired product. ?H NMR (400 MHz, DMSO-d6) oe 0.96 (t, J = 7.2 Hz, 3H), 2.28-2.5 1 (m,1OH), 3.72 (s, 2H), 8.09 (d, J= 8.4 Hz, 1H), 8.40 (s, 1H), 8.51 (dd, J, = 2.4 Hz, J2 = 8.8 Hz,1H)., 5308-25-8

As the paragraph descriping shows that 5308-25-8 is playing an increasingly important role.

Reference£º
Patent; GLENMARK PHARMACEUTICALS S.A.; PATEL, Vinod; REDDY, Venkateshwar; GHARAT, Laxmikant Atmaram; CHAUDHARI, Sachin Sundarlal; DAS, Sanjib; VELGALETI, Ranganadh; SHAH, Daisy Manish; BAJPAI, Malini; (262 pag.)WO2018/215668; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5308-25-8,1-Ethylpiperazine,as a common compound, the synthetic route is as follows.

1-Ethyl-4-(3-nitro-phenyl)-piperazineA mixture of 1-fiuoro-3-nitrobenzene (3.2 mL, 29.7 mmol) and N-ethyl-piperazine (7.6 mL, 59.4 mmol, 2 equiv) is heated to reflux and stirred for 117h. The reaction mixture is allowed to cool to RT and diluted with H2O (40 mL) and DCM/MeOH (9:1 , 80 mL). The aqueous layer is separated and extracted with DCM/MeOH (9:1). The organic phase is washed with brine, dried (Na2SO4), filtered and concentrated. Purification of the crude product by silica gel column chromatography (DCM/MeOH, 1 :0 ? 95:5) affords the title compound as a brown oil: ESI-MS: 236.0 [MH]+; tR= 2.49 min (purity: 99%, system 1 ); TLC: R, – 0.26 (DCM/MeOH, 95:5)., 5308-25-8

The synthetic route of 5308-25-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GmbH; WO2007/71752; (2007); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics